Globally recognized leader in early-phase oncology clinical development and experimental therapeuticsStrengthens strategic ...
Potentially first-in-class oral TNIK inhibitor advances into late-stage development after milestones marked by vital ...
Morning Overview on MSN
A nasal spray reversed signs of brain aging in early tests, and a patent is already filed
Researchers at Texas A&M University reported that two intranasal doses of extracellular vesicles derived from human neural ...
18h
Breakthrough T1D Awards Grant to Support PRISE‑hATG Study of SAB‑142 in Stage 3 Type 1 Diabetes
Breakthrough T1D, the leading global type 1 diabetes (T1D) research and advocacy organization and SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a ...
The gut microbiome is no longer viewed as a mere spectator in cancer development – it is increasingly recognized as a key ...
Cancer remains notoriously difficult to treat, partly because tumors co‑opt their surrounding environment, including the ...
Breakthrough T1D, the leading global type 1 diabetes (T1D) research and advocacy organization and SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical ...
Texas A&M will receive more than $6 million in NIH funding to study how alcohol and cocaine affect cognition. The goal of the ...
Radiation therapy remains a central modality in cancer treatment, but normal-tissue toxicity and long-term stochastic effects ...
Background Janus kinase inhibitors (JAKis) are emerging therapies for SLE, but concerns regarding thromboembolic risk persist ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results